Epstein-Barr virus infections and their association with human malignancies: some key questions

References

• Rickinson A B, Kieff Epstein E., Fields BN, Knipe DM, Howley PM, et al. Fields Virology, 3rd edn. Lippincott-Raven Publishers, Philadelphia, PA 1996; 2397–437, Barr virus
   Google Scholar
• Barel M, Balbo M, Gauffre A, Frade R. Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear pl20 ribo-nucleoprotein. Mol Immunol 1995; 32: 389–97
   PubMedGoogle Scholar
• Knox P G, Li Q X, Rickinson A B, Young L S. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virusxell interaction observed in nasopharyngeal carcinoma. Virology 1996; 215: 40–50
   PubMed Web of Science ®Google Scholar
• Tsoukas C D, Lambris J D. Expression of EBV/C3d receptors on T cells: biological significance. Immunol Today 1993; 14: 56–9
   PubMedGoogle Scholar
• Yoshiyama H, Imai S, Shimizu N, Takada K. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. J Virol 1997; 71: 5688–91
   PubMed Web of Science ®Google Scholar
• Gratama J W, Oosterveer M AP, Zwaan F E, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for the site of viral latency. Proc Natl Acad Sci USA 1988; 85: 8693–7
   PubMed Web of Science ®Google Scholar
• Gratama J W, Lennette E T, Lonnqvist B, et al. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Virol 1992; 37: 39–47
   PubMed Web of Science ®Google Scholar
• Allday MJ, Crawford D H. Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. Lancet 1988; 1: 855–7
   PubMed Web of Science ®Google Scholar
• Bayliss G H, Wolf H. An Epstein-Barr virus early protein induces cell fusion. Proc Natl Acad Sci USA 1981; 3: 7162–5
   Google Scholar
• Miyashita E M, Yang B, Lam K MC, Grawford D H, Thorley-Dawson D A. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995; 80: 593–601
   PubMed Web of Science ®Google Scholar
• Dimitrov D S. How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell 1997; 91: 721–30
   PubMed Web of Science ®Google Scholar
• Kieff E. Fields Virology, 3rd edn. Lippincott-Raven Publishers, Philadelphia, PA 1996; 2343–96
   Google Scholar
• Baer R, Bankier A T, Biggin M D, et al. DNA sequence and expression of the B95–8 Epstein-Barr virus genome. Nature 1984; 310: 207–11
   PubMed Web of Science ®Google Scholar
• Knecht H, Bachmann E, Brousett P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82: 2937–42
   PubMed Web of Science ®Google Scholar
• Khan G, Naase M A. Down-regulation of Epstein-Barr virus nuclear antigen 1 in Reed-Sternberg cells of Hodgkin's disease. J Clin Pathol 1995; 48: 845–8
   PubMed Web of Science ®Google Scholar
• Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol 1995; 69: 231–8
   PubMed Web of Science ®Google Scholar
• Robertson E, Kieff E. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J Virol 1995; 69: 983–93
   PubMed Web of Science ®Google Scholar
• Griffin B E, Karran L. Immortalization of monkey epithelial cells by specific fragments of Epstein-Barr virus DNA. Nature 1984; 309: 78–82
   PubMed Web of Science ®Google Scholar
• Karran L, Teo C G, King D, et al. Establishment of immortalized primate epithelial cells with sub-genomic EBV DNA. Lnt J Cancer 1990; 45: 763–72
   PubMed Web of Science ®Google Scholar
• Hitt M M, Allday M J, Hara T, et al. EBV gene expression in an NPC-related tumour. EMBO J 1989; 8: 2639–51
   PubMed Web of Science ®Google Scholar
• Wei M X, Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J 1989; 8: 2897–903
   Google Scholar
• vanGorp J, Brink A, Oudejans J J, et al. Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas. J Clin Pathol 1996; 49: 72–6
   PubMed Web of Science ®Google Scholar
• Wen S, Mizugaki Y, Shinozaki Takada K. Epstein-Barr virus (EBV) infection in salivary gland tumors: lytic EBV infection in nonmalignant epithelial cells surrounded by EBV-positive T-lymphoma cells. Virology 1997; 227: 72–6
   Web of Science ®Google Scholar
• Snudden D K, Smith P R, Lai DNg M-H, Griffin B E. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene 1995; 10: 1545–52
   PubMed Web of Science ®Google Scholar
• Wrightham M N, Stewart J P, Janjua N K, et al. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology 1995; 208: 521–30
   PubMed Web of Science ®Google Scholar
• Bhatia K, Raj A, Gutierrez M I, et al. Variation in the sequence of Epstein-Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphoma. Oncogene 1996; 13: 177–81
   PubMed Web of Science ®Google Scholar
• Knecht H, Bachmann E, Brousset P, et al. Mutational hot spots within the carboxy terminal regions of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoprohferative disorders. Oncogene 1995; 10: 523–8
   PubMed Web of Science ®Google Scholar
• Polack A, Hortnagel K, Pajic A, et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-trans-formed cells independent of EBV nuclear antigen 2 and latent membrane protein. Proc Natl Acad Sci USA 1996; 93: 10411–6
   PubMed Web of Science ®Google Scholar
• Johnson J M, Yu M T, Carroll W L. c-myc hypermutation is ongoing in endemic, but not all Burkitt's lymphoma. Blood 1991; 78: 2419–25
   PubMed Web of Science ®Google Scholar
• Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56–61
   PubMed Web of Science ®Google Scholar
• Vaux D L, Cory S, Adams J M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–2
   PubMed Web of Science ®Google Scholar
• Kondo E, Nakamura S, Onoue H, et al. Detection of bcl-2 protein and bcl-2 and messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood 1992; 80: 2044–51
   PubMed Web of Science ®Google Scholar
• Murray P G, Swinnen L J, Constandinou C M, et al. Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRFI, is commonly expressed in post transplantation lympho-proliferative disorders. Blood 1996; 87: 706–11
   PubMed Web of Science ®Google Scholar
• Chiang A KS, Tao Q, Srivastava G, Ho F CS, Nasal N K. T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. lnt J Cancer 1996; 68: 285–90
   PubMed Web of Science ®Google Scholar
• Miyazaki I, Cheung R G, Dosch H-M. Viral interleukin-10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 1993; 178: 439–47
   PubMed Web of Science ®Google Scholar
• Ohshima K, Suzumiya J, Akamatu M, Takeshita M, Kikuchi M. Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. lnt J Cancer 1995; 62: 5–10
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tahara H, Narula S, Moore K W, Robbins P D, Lotze M T. Viral interleukin 10 (IL-10), the human herpes 4 cellular IL-10 homologue, induces local synergy to allogeneic and syngeneic tumors. J Exp Med 1995; 182: 477–86
   PubMed Web of Science ®Google Scholar
• Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881–922
   PubMed Web of Science ®Google Scholar
• Zimber-Strobl U, Kempkes B, Marschall G. et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J 1996; 15: 7070–8
   Google Scholar
• Srinivas S K, Sixbey J W. Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol 1995; 69: 8155–8
   PubMed Web of Science ®Google Scholar
• Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809–19
   PubMed Web of Science ®Google Scholar
• Heim S. Genetic Instability in Cancer, Cancer SurveysLindahlT. Cold Spring Harbor Press Cold Spring Harbor NY 1996; 28: 247–60
   Google Scholar
• Arrand J R, Walsh-Arrand J E, Rymo L. Cytoplasmic RNA from normal and malignant human cells shows homology to the DNAs of Epstein-Barr virus and human adenoviruses. EMBO J 1983; 10: 1673–83
   Google Scholar
• Lo K-W, Huang D P, Lau K-M. pl6 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995; 55: 2039–43
   PubMed Web of Science ®Google Scholar
• Rowe M, Rowe D T, Gregory C D, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J 1987; 6: 2743–51
   PubMed Web of Science ®Google Scholar
• Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685–8
   PubMed Web of Science ®Google Scholar
• Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995; 86: 659–65
   PubMed Web of Science ®Google Scholar
• Miller G. The switch between latency and replication of Epstein-Barr. virus. J Infect Dis 1990; 161: 833–44
   PubMed Web of Science ®Google Scholar
• Labrecque L G. Epstein-Barr Virus in Lymphoid and Epithelial Cell Lines and Tumours dissertation. University of London, UK 1996
   Google Scholar
• Elliott S L, Pye S J, Schmidt C, Cross S M, Silins S L, Misko I S. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. J Infect Dis 1997; 176: 1066–72
   Web of Science ®Google Scholar
• Austin P J, Flemington E, Yandava C N, Strominger J L, Speck S H. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci USA 1988; 85: 3678–82
   PubMed Web of Science ®Google Scholar
• Lau R, Packham G, Farrell P J. Differential splicing of Epstein-Barr virus immediate-early RNA. J Virol 1992; 66: 6233–6
   PubMed Web of Science ®Google Scholar
• Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197: 358–65
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I, Hummel M. Epstein-Barr virus in tumours. Histopathology 1996; 29: 297–315
   PubMed Web of Science ®Google Scholar
• Labrecque L G, Barnes D M, Fentiman I S, Griffin B E. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995; 55: 39–45
   PubMed Web of Science ®Google Scholar
• Wolf J, Jox A, Skarbek H, et al. Selective loss of integrated Epstein-Barr virus genomes after long-term cultivation of Burkitt's lymphoma x B-lymphoblastoid cell hybrids due to chromatin instability at the integration site. Virology 1995; 212: 179–85
   PubMed Web of Science ®Google Scholar
• Razzouk B I, Srinivas S, Sample C E, Singh V, Sixbey H W. Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996; 173: 529–35
   PubMed Web of Science ®Google Scholar